NCT00002249已完成1 期
A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV infection.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients must have the following:
- •HIV infection.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Active opportunistic infection or neoplasm.
- •High likelihood of death during study.
- •Significant ophthalmologic, renal, hepatic, cardiovascular, hematologic, neurologic, psychiatric,respiratory, or metabolic disease.
- •Donation of > 1 unit blood or acute loss of blood within one month of study entry.
- •Patients with the following prior conditions are excluded:
- •History of opportunistic infection.
- •Previous allergic reaction to ciprofloxacin, norfloxacin, or any other quinolone.
- •Prior Medication:
- •Use of any investigational agent within 7 days of entry into study. Use of any medication within 3 days prior to entry (7 days for AZT). Alcohol or drug abuse.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's SarcomaHIV PositiveKaposi's SarcomaAIDSNCT02029430ImmunityBio, Inc.15
撤回
4 期
Pharmacotherapy for HIV Infected Patients With Alcohol ProblemsHIV InfectionHeavy Alcoholic ConsumptionHIV InfectionsNCT00854230VA Connecticut Healthcare System
已完成
1 期
A Study of LXR015-1 in HIV-Infected PatientsHIV InfectionsNCT00002365LXR Biotechnology30
已完成
不适用
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With AnemiaCytopeniasHIV InfectionsNCT00002042Ortho Pharmaceuticals
进行中（未招募）
1 期
Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)HIVTuberculosisNCT05122767The Aurum Institute NPC92